ClinicalTrials.gg
CompletedNCT05217355Updated Feb 24, 2023

A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines

A Phase 2 interventional study of MBA-P01 (Botulinum toxin A) and Placebo in Glabellar Frown Lines, sponsored by Medytox Korea. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by Medytox Korea (part of Medy-Tox) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

This study is intended to evaluate the efficacy and safety of MBA-P01 compared to placebo in treatment of glabellar lines.

02

Conditions studied

  • Glabellar Frown Lines
03

In context

Lead sponsor

Medytox Korea is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged between 19 and 65
  • Patients attaining ≥grade 2 (moderate) in the investigator's rating of the severity of glabella lines at maximum frown
  • Patients who voluntarily sign the

Exclusion criteria

Exclusion Criteria:

  • Patients with the history of facial nerve paralysis
  • Patients with the symptoms of eyelid ptosis determined by the investigator
  • Marked facial asymmetry, dermatochalasis, deep dermal scarring in the glabellar area, excessively thick sebaceous skin, or the inability to substantially lessen glabellar lines even by physically spreading them apart, as determined by the investigator
  • Active skin disease or infection in the treatment area
  • History of surgery which may habe altered the anatomy of the corrugator supercilia muscle or the procerus muscle or related nerve
  • Prior treatment with permanent filers, synthetic implantation, and/or autologous fat transplantation in the treatment area
  • Subject who received the following drugs within 4 weeks prior to the screening

    1. muscle relaxant: Peripherally acting relaxants, Centrally acting muscle relaxants, skeletal muscle relaxants
    2. benzodiazepine: Diazepam, Chlodiazepoxide, Medazepam, Oxazepam, Potassium clorazepate, Lorazepam etc.

      • Subject who takes Muscle relaxants and benzodiazepine stably for 4 weeks can participate the study
  • Subject who reveived any of the below facial aesthetic treatments that, in the investigator's opinion, could interfere the evaluation of efficacy

    1. Prior treatment with fillers in the treatment area within 1 year prior to screening (CaHA, Hyaluronic acid, PLLA, PCL etc.)
    2. Facial resurfacing or skin tightening procedure with lase, light or radiofrequency-based system; or any medium depth or deep depth facial chemical peels in the upper face within 6 months prior to screening
  • Subject who received Retinois following period

    1. Systemic drug delivery : within 6 months prior to the screening
    2. Local drug delivery : within 3 months prior to the screening
  • Patients with medical conditions who may be at greater risk due to the administration of the drugs (e.g.. diseases that may affect the neuromuscular action including Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis and motor neuropathy)
  • Known immunization or to any botulinum toxin preparations
  • Subject who had botulinum toxin treatment within 6 months prior to the screening or planning to receive botulinum toxic treatment during the study period other than study treatment
  • Female subjects who are pregnant or nursing, or planning a pregnancy during the study and female subjects of who are not willing to use acceptable form of sontraception
  • Subject who are participating in other interventional clinical study or have participated in such a study within 30 dyas prior to screening
  • Subjects who are not eligible for this study at the discretion of the investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    MBA-P01

    Experimental group, Dose: 20U

    Drug: MBA-P01 (Botulinum toxin A)

  • Placebo comparator
    Placebo

    Placebo gorup, Normal saline

    Drug: Placebo

Interventions

  • MBA-P01 will be injected into the Glabellar line

  • DrugPlacebo

    Placebo will be injected into the Glabellar line

06

What researchers measure

Primary outcomes

  1. Facial Wrinkle Scale(FWS) change

    Proportion of subjects achieving at least a 2-grade decrease from baseline in score of Facial Wrinkle Scale (FWS) (0:none to 3: severe) of Glabellar line at maximum frown

    Time frame: 4 weeks

Secondary outcomes

  1. Investigator-rated improvement rate of glabellar lines at maximum frown

    The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.

    Time frame: Week 8, 12, 16

  2. Investigator-rated improvement rate of glabellar lines at rest

    The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.

    Time frame: Week 4, 8, 12, 16

  3. Participant-rated improvement rate of glabellar lines at maximum frown

    The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.

    Time frame: Week 4, 8, 12, 16

  4. Participant-rated improvement rate of glabellar lines at rest

    The investigator and participant evaluate the participant's GL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe.

    Time frame: Week 4, 8, 12, 16

  5. Participant-rated satisfaction after treatment

    Proportion of subject achieving at least 5 score in Participant-rated satisfaction

    Time frame: Week 4, 8, 12, 16

07

Study locations

1 site
  • Chung-And Univ. Hospital
    Seoul, Dongjak-gu 156-755, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Jun 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Feb 1, 2022
StartActual
Dec 28, 2021
Primary completionActual
Jun 22, 2022
CompletionActual
Jun 22, 2022
Last update
Feb 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05217355
Lead sponsor
Medytox Korea
Responsible party
Sponsor
First posted
Feb 1, 2022
Start date
Dec 28, 2021
Primary completion
Jun 22, 2022
Completion
Jun 22, 2022
Last update
Feb 24, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion